Advanced Skin Cancer Diagnostic Tests Overlay Biology on Top of Pathology to Determine Appropriate Treatment With Derek Maetzold Castle Bio TRANSCRIPT

Derek Maetzold, President and CEO, Castle Biosciences is harnessing the power of genomics to understand the biology of skin cancer. Castle has developed genomic tests to determine how aggressive melanoma and squamous cell carcinoma are in order to better inform dermatologist and patients about intervention decisions. With both diagnostic and prognostic tests and assist from artificial intelligence machine learning-based algorithms, calculations are made for assessing the risk of developing metastatic disease for each individual patient.

@CastleBio #SkinCancer #Melanoma #SquamousCellCarcinoma #GenomicTesting #Dermatology

Listen to the podcast here

Share on facebook
Share on twitter
Share on linkedin
Related Post


Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.